Table 2.
Patient characteristics of the validation cohort.
| (n = 145) | |
| Clinical characteristics | |
| Sex, n (%) | |
| Male | 72 (49.7) |
| Female | 73 (50.3) |
| Age | |
| Median, n (range) | 62 (20–90) |
| Location of tumor, n (%) | |
| Trunk | 29 (20.0) |
| Extremity | 16 (11.0) |
| Unknown | 100 (69.0) |
| Pathologic characteristics | |
| Depth (mm) | |
| Median, n (range) | 2.75 (0.15–13.00) |
| Ulceration, n (%) | |
| Absent | 81 (55.9) |
| Present | 64 (44.1) |
| Unknown | 0 (0.0) |
| TILs | |
| Absent | 17 (11.7) |
| Non-brisk | 108 (74.5) |
| Brisk | 19 (13.1) |
| Unknown | 1 (0.7) |
| Microsatellite lesions, n (%) | |
| Absent | 114 (78.6) |
| Present | 31 (21.4) |
| Unknown | 0 (0.0) |
| Staging characteristics | |
| T-stage, n (%) | |
| T1a or T1b | 23 (15.9) |
| T2a | 14 (9.7) |
| T2b or T3a | 44 (30.3) |
| T3b or T4a | 40 (27.6) |
| T4b | 24 (16.5) |
| SLNB status, n (%) | |
| Completed | 41 (28.3) |
| Positive, n (% of completed) | 19 (46.3) |
| Negative, n (% of completed) | 22 (53.7) |
| Not completed | 4 (2.8) |
| Unknown | 100 (68.9) |
| Stage, n (%) | |
| I | 31 (21.4) |
| II | 66 (45.5) |
| III | 48 (33.1) |
| Outcome characteristics | |
| Patient follow-up (months) | |
| Median, n (range) | 72.5 (1.4–456.2) |
| DMR, n (%) | |
| Distant recurrence | 69 (47.6) |
| No distant recurrence or local recurrence only | 76 (52.4) |
| OS, n (%) | |
| Alive (at least 2 years) | 97 (66.9) |
| Dead | 48 (33.1) |
| DSS, n (%) | |
| Alive or NED at death | 82 (56.6) |
| Median follow-up (months) | 99.8 |
| Dead with melanoma | 63 (43.4) |
| Median follow-up (months) | 33.0 |
| Unknown | 0 (0.0) |
DMR distant metastatic recurrence, DSS disease-specific survival, NED no evidence of disease, OS overall survival.